Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Amphastar Pharmaceuticals (NASDAQ:AMPH) has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company will be represented by CFO Bill Peters and SVP of Corp. Communication Dan Dischner in an analyst-moderated fireside chat scheduled for Wednesday, April 9th, 2025, at 1:30 pm ET.
The presentation will be accessible through Amphastar's investor relations website at http://ir.amphastar.com, with the webcast remaining available for 30 days following the event.
Amphastar Pharmaceuticals (NASDAQ:AMPH) ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute. L'azienda sarà rappresentata dal CFO Bill Peters e dal SVP della Comunicazione Aziendale Dan Dischner in una chiacchierata informale moderata da un analista, programmata per mercoledì 9 aprile 2025, alle 13:30 ET.
La presentazione sarà accessibile attraverso il sito web delle relazioni con gli investitori di Amphastar all'indirizzo http://ir.amphastar.com, con il webcast che rimarrà disponibile per 30 giorni dopo l'evento.
Amphastar Pharmaceuticals (NASDAQ:AMPH) ha anunciado su participación en la 24ª Conferencia Virtual Anual de Salud de Needham. La empresa estará representada por el CFO Bill Peters y el SVP de Comunicación Corporativa Dan Dischner en una charla informal moderada por un analista, programada para miércoles 9 de abril de 2025, a la 1:30 pm ET.
La presentación estará disponible a través del sitio web de relaciones con inversionistas de Amphastar en http://ir.amphastar.com, con el webcast disponible durante 30 días después del evento.
Amphastar Pharmaceuticals (NASDAQ:AMPH)는 제24회 니드햄 가상 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사는 CFO Bill Peters와 기업 커뮤니케이션 SVP Dan Dischner가 진행하는 애널리스트 주관의 파이어사이드 챗에 참석할 예정이며, 이는 2025년 4월 9일 수요일 오후 1시 30분 ET에 예정되어 있습니다.
발표는 Amphastar의 투자자 관계 웹사이트 http://ir.amphastar.com를 통해 접근할 수 있으며, 웹캐스트는 이벤트 이후 30일 동안 이용 가능합니다.
Amphastar Pharmaceuticals (NASDAQ:AMPH) a annoncé sa participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé. L'entreprise sera représentée par le CFO Bill Peters et le SVP de la Communication d'Entreprise Dan Dischner lors d'une discussion informelle modérée par un analyste, prévue pour mercredi 9 avril 2025, à 13h30 ET.
La présentation sera accessible via le site web des relations avec les investisseurs d'Amphastar à l'adresse http://ir.amphastar.com, le webcast restant disponible pendant 30 jours après l'événement.
Amphastar Pharmaceuticals (NASDAQ:AMPH) hat seine Teilnahme an der 24. jährlichen Needham virtuellen Gesundheitskonferenz angekündigt. Das Unternehmen wird durch CFO Bill Peters und SVP der Unternehmenskommunikation Dan Dischner in einem von einem Analysten moderierten Fireside-Chat vertreten sein, der für Mittwoch, den 9. April 2025, um 13:30 Uhr ET geplant ist.
Die Präsentation wird über die Investor-Relations-Website von Amphastar unter http://ir.amphastar.com zugänglich sein, wobei der Webcast für 30 Tage nach der Veranstaltung verfügbar bleibt.
- None.
- None.
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 3, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th, 2025, at 1:30 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
About Amphastar:
Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company's website at www.amphastar.com.
The Amphastar Pharmaceuticals' logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene MIST®, Amphadase®, Cortrosyn®, REXTOVY® and BAQSIMI® are the property of Amphastar Pharmaceuticals, Inc.
Forward Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits BAQSIMI®, including its potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025 and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact:
Bill Peters
Chief Financial Officer
(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire